Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Background CheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with improved safety and tolerability. This analysis assesses the long‐term clinical benefits of nivolumab versus everolimus. Methods The randomized, open‐la...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Cancer Ročník 126; číslo 18; s. 4156 - 4167
Hlavní autori:	Motzer, Robert J., Escudier, Bernard, George, Saby, Hammers, Hans J., Srinivas, Sandhya, Tykodi, Scott S., Sosman, Jeffrey A., Plimack, Elizabeth R., Procopio, Giuseppe, McDermott, David F., Castellano, Daniel, Choueiri, Toni K., Donskov, Frede, Gurney, Howard, Oudard, Stéphane, Richardet, Martin, Peltola, Katriina, Alva, Ajjai S., Carducci, Michael, Wagstaff, John, Chevreau, Christine, Fukasawa, Satoshi, Tomita, Yoshihiko, Gauler, Thomas C., Kollmannsberger, Christian K., Schutz, Fabio A., Larkin, James, Cella, David, McHenry, M. Brent, Saggi, Shruti Shally, Tannir, Nizar M.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Wiley Subscription Services, Inc 15.09.2020
Predmet:	advanced renal cell carcinoma (aRCC) Antiangiogenics Cancer CheckMate 025 Clear cell-type renal cell carcinoma everolimus Fatigue immune checkpoint inhibitor Immune checkpoint inhibitors Immunotherapy Inhibitor drugs Kidney cancer Kidneys Monoclonal antibodies nivolumab Oncology Patients previously treated Pruritus Quality of life Randomization Renal cell carcinoma Safety Safety management Stomatitis Survival Targeted cancer therapy Toxicity previously treated CheckMate 025 advanced renal cell carcinoma (aRCC) everolimus immune checkpoint inhibitor nivolumab
ISSN:	0008-543X, 1097-0142, 1097-0142
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!